Pap smears suck. This tampon-like device lets you screen for cervical cancer at home
It's not a pleasant experience. You'll lie down with your legs in stirrups, while your doctor inserts a speculum inside your vagina. Then, she or he will take a sample from your cervix with a hard plastic device to figure out if you have any trace of HPV (the human papillomavirus), a sexually transmitted infection that can cause cervical cancer, or cancerous and precancerous cells.
Starting today, however, there's an easier solution. Teal Health, a woman's health company founded in 2020, has developed a new product that allows you to take a sample at home and send it to a lab for testing. Today, the device received FDA approval, so it is now possible to order one online. It will be covered by insurance. The company is still working on out-of-pocket pricing, but aims to make the product as affordable and accessible for women as possible.
Teal was founded by Kara Egan, a health tech investor, and Avnesh Thako, an interventional radiologist and Stanford School of Medicine professor. Egan realized that many women were skipping their pap smears. (In 2019, 23% of women were overdue for their cervical cancer screening.) But cervical cancer is the fourth deadliest cancer among women. 'It's just so easy to accidentally skip your appointment,' says Egan. 'That's especially true if you don't have insurance or don't have a doctor you see regularly.'
Some proportion of women also skip their pap smear because the process itself is so uncomfortable. 'It can feel like a very violating experience, but it is also so important,' Egan says.
How Teal works
Working with the design studio Ideo, Egan and Thako have developed a device that looks a like a tampon and is designed be comfortable to insert with a plastic applicator. Ideo designed the wand so women could use it with one hand while standing up while in the bathroom.
A woman will insert the wand into her vagina and use a thumb-operated wheel to deploy a sponge at the tip. Spinning the sponge collects cell samples from the cervix. From there, she can use the wheel to retract the sponge back into the wand to prevent contamination. The sponge pops off the applicator, and is then sent to a lab where it will be tested.
Teal is a telemedicine platform. When you buy the wand, you will see a doctor online who will walk you through the process of using the device. If the results come back abnormal, the doctor will walk through the results with you and also talk about the next steps, which likely will involve seeing a doctor and following some sort of treatment plan.
Part of what motivated Egan to pursue this device is that cervical cancer can be easily treated with early testing. HPV is a common virus that is commonly spread through sex or skin-to-skin contact. These is now a vaccine that pediatricians give to both girls and boys that reduces the risk of contracting HPV. Most HVP infections don't lead to cancer. But if even a woman does get infected with HVP, it is relatively easy to clear the infection if it is detected early enough.
By taking a sample of cervical cells, we are now able to identify the 14 different kinds of pre-cancerous cells associated with cervical cancer. 'If you screen for cervical cancer and catch it early, it is nearly 100% curable,' says Egan.
After developing the wand, Teal health has done clinical trials to identify its effectiveness. Then, the company sent the results to the FDA to get approval to start selling the device. That approval came through today.
Teal's wand will be available through the brand's website. The product will be covered by insurance. But the company also wants to make it available to women who aren't covered by insurance. It hasn't established the out-of-pocket cost yet, but Egan promises that the final pricing will be as affordable to as many women as possible. It will also have a donation program, so that some women can get the test for free. 'We will find ways for people who don't have the means to make sure they're still accessing screening,' she says. 'No one needs to get cervical cancer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
CAMBRIDGE, Mass., Aug. 19, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies plan to co-identify targets and discover first-in-class or best-in-class drug candidates using XtalPi's proprietary AI-driven drug discovery platform. The XtalPi platform combines the speed and generative power of AI with the accuracy of its robotic lab-in-the-loop to accelerate drug discovery and vastly expand the explorable chemical space. This integrated workflow spans deep-learning-based molecule design, quantum physics and molecular dynamics simulations for predicting drug-target interactions, automated chemical synthesis, and experimental validation of candidate compounds' key pharmaceutical properties. Leveraging its expertise in immunology and inflammation as well as its experience in small molecule drug development, Dong-A ST will actively participate throughout the entire R&D process—including candidate validation, efficacy and safety testing, and the formulation of preclinical and clinical development strategies. The company also plans to explore strategies for pipeline expansion and assess commercialization potential. Through this partnership, Dong-A ST aims to strengthen its pipeline in the immunology and inflammation space and expand its R&D scope beyond small molecule therapeutics into areas such as targeted protein degradation (TPD), biologics, antibody-drug conjugates (ADC), and gene therapies. John Wang, Senior Vice President of Drug Discovery at XtalPi, stated: "The combination of Dong-A ST's extensive expertise and XtalPi's proven AI-robotics platform is well-positioned to translate scientific innovation into competitive precision medicines. Together, we aim to rapidly discover and rigorously validate novel drug candidates across multiple modalities to unlock unique market opportunities, and deliver transformative therapies for global patients." Jae-Hong Park, Head of R&D at Dong-A ST, remarked, "This collaboration marks a pivotal step in expanding Dong-A ST's R&D capabilities," adding, "By leveraging synergies with XtalPi's AI platform, we expect to accelerate the development of next-generation treatments for immune and inflammatory diseases." Meanwhile, both Dong-A ST and XtalPi operate open innovation offices in Boston, USA. This geographic proximity will facilitate closer and more efficient collaboration throughout the drug discovery process. About Dong-A ST Dong-A ST Co., Ltd. ( was established in 1932 and is a leading Korean pharmaceutical company engaged in the development, manufacturing, and commercialization of ethical drugs, biosimilars, medical devices, and diagnostics. Its key products include Stillen (gastritis), Zydena (erectile dysfunction), Motilitone (functional dyspepsia), and Imuldosa (ustekinuma biosimilar). Leveraging strong R&D capabilities and a history of innovation, Dong-A ST is expanding its pipeline in immunology, inflammation, neurological disease, metabolic diseases, and oncology, while advancing into new modalities such as biologics, ADCs, TPD, and gene therapies. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc. Sign in to access your portfolio
CNN
25 minutes ago
- CNN
FDA warns against eating certain shrimp sold at Walmart amid investigation into radioactive contamination
Federal agencies Food & healthFacebookTweetLink Follow The US Food and Drug Administration on Tuesday urged the public not to eat certain bags of frozen raw shrimp sold at Walmart, citing concerns about unsanitary conditions and radioactive contamination found in shipments from the same supplier. The FDA said that a radioactive isotope, cesium-137, was detected in a sample of breaded shrimp detained at US ports – in Los Angeles, Houston, Savannah, and Miami – from an Indonesian supplier named BMS Foods. Those contaminated shipments never reached the US market. However, because Walmart's raw frozen shrimp came from the same supplier – and the agency said it 'appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137' – officials advised consumers to avoid eating them. The levels of cesium detected – about 68 becquerels per kilogram – were well below the FDA's intervention level of 1,200 Bq/kg. Still, regulators issued the advisory out of caution, citing the potential risks of cancer from long-term, low-dose exposure and problems at the supplier's facility. The advisory applies to 2-pound Great Value bags of white vannamei shrimp, all carrying a best-by date of March 15, 2027. They were distributed to Walmart stores in at least 13 states: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. The agency is advising consumers who purchased the shrimp to throw it away or return it, and, said an investigation is ongoing in conjunction with Indonesian seafood regulatory authorities. Walmart confirmed to CNN that it 'immediately recalled the product from impacted stores.' CNN has also reached out to the supplier for comment.
CNN
26 minutes ago
- CNN
FDA warns against eating certain shrimp sold at Walmart amid investigation into radioactive contamination
The US Food and Drug Administration on Tuesday urged the public not to eat certain bags of frozen raw shrimp sold at Walmart, citing concerns about unsanitary conditions and radioactive contamination found in shipments from the same supplier. The FDA said that a radioactive isotope, cesium-137, was detected in a sample of breaded shrimp detained at US ports – in Los Angeles, Houston, Savannah, and Miami – from an Indonesian supplier named BMS Foods. Those contaminated shipments never reached the US market. However, because Walmart's raw frozen shrimp came from the same supplier – and the agency said it 'appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137' – officials advised consumers to avoid eating them. The levels of cesium detected – about 68 becquerels per kilogram – were well below the FDA's intervention level of 1,200 Bq/kg. Still, regulators issued the advisory out of caution, citing the potential risks of cancer from long-term, low-dose exposure and problems at the supplier's facility. The advisory applies to 2-pound Great Value bags of white vannamei shrimp, all carrying a best-by date of March 15, 2027. They were distributed to Walmart stores in at least 13 states: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. The agency is advising consumers who purchased the shrimp to throw it away or return it, and, said an investigation is ongoing in conjunction with Indonesian seafood regulatory authorities. Walmart confirmed to CNN that it 'immediately recalled the product from impacted stores.' CNN has also reached out to the supplier for comment.
